Fig. 3: Mean change in BCVA from baseline to Week 64. | Eye

Fig. 3: Mean change in BCVA from baseline to Week 64.

From: TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration

Fig. 3

Pre-specified secondary endpoint. AFL aflibercept, ANOVA Analysis of variance, BCVA best-corrected visual acuity, BRO brolucizumab, CI confidence interval, LOCF Last Observation Carried Forward, LS least squares, SE standard error. LOCF. ANOVA model with treatment arm (factor), baseline BCVA categories (≤54, 55 to ≤73, ≥74 letters), and age categories (<75 years, ≥75 years) as fixed effects. BCVA values collected after the start of an alternative treatment were replaced by the last value prior to start of alternative treatment. If Week 60 BCVA value is not available, Week 62 BCVA is used; otherwise LOCF is applied. The primary objective was met upon significance of both non-inferiority of average change in BCVA from baseline at Weeks 28 and 32 and superiority of distribution of the last interval without DA up to Week 32.

Back to article page